InnoCan Pharma Corporation (CSE: INNO)
Canada
· Delayed Price · Currency is CAD 0.235
+0.025 (11.90%)
Nov 21, 2024, 11:31 AM EST
InnoCan Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 24.39 | 13.66 | 2.56 | 0.2 | 0.01 | - | Upgrade
|
| Revenue Growth (YoY) | 271.49% | 433.69% | 1205.61% | 2350.00% | - | - | Upgrade
|
| Cost of Revenue | 2.44 | 1.68 | 0.45 | 0.08 | 0.01 | - | Upgrade
|
| Gross Profit | 21.95 | 11.98 | 2.11 | 0.12 | 0 | - | Upgrade
|
| Selling, General & Admin | 22.95 | 13.99 | 6.85 | 6.2 | 2.98 | 2.63 | Upgrade
|
| Research & Development | 1.78 | 1.8 | 1.53 | 1.4 | 1.74 | 0.37 | Upgrade
|
| Operating Expenses | 24.73 | 15.78 | 8.37 | 7.6 | 4.73 | 3 | Upgrade
|
| Operating Income | -2.78 | -3.8 | -6.27 | -7.48 | -4.73 | -3 | Upgrade
|
| Interest Expense | - | - | -0 | -0.01 | -0.01 | -0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.19 | 0 | -0.42 | -0.29 | 0.03 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.77 | -0.24 | 2.8 | -2.31 | -5.25 | -0.29 | Upgrade
|
| Pretax Income | -2.2 | -4.03 | -3.89 | -10.09 | -9.95 | -3.34 | Upgrade
|
| Income Tax Expense | 0.93 | 0.21 | 0 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -3.12 | -4.25 | -3.89 | -10.09 | -9.95 | -3.34 | Upgrade
|
| Minority Interest in Earnings | -1.22 | -0.45 | 0.13 | 0.04 | - | - | Upgrade
|
| Net Income | -4.34 | -4.7 | -3.76 | -10.05 | -9.95 | -3.34 | Upgrade
|
| Net Income to Common | -4.34 | -4.7 | -3.76 | -10.05 | -9.95 | -3.34 | Upgrade
|
| Shares Outstanding (Basic) | 269 | 257 | 249 | 225 | 162 | 121 | Upgrade
|
| Shares Outstanding (Diluted) | 269 | 257 | 249 | 225 | 162 | 121 | Upgrade
|
| Shares Change (YoY) | 7.44% | 3.23% | 10.87% | 38.59% | 34.30% | 42.85% | Upgrade
|
| EPS (Basic) | -0.02 | -0.02 | -0.02 | -0.04 | -0.06 | -0.03 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.02 | -0.02 | -0.04 | -0.06 | -0.03 | Upgrade
|
| Free Cash Flow | -2.12 | -3.95 | -6.09 | -6.67 | -3.69 | -2.72 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 | Upgrade
|
| Gross Margin | 90.01% | 87.71% | 82.34% | 61.73% | 37.50% | - | Upgrade
|
| Operating Margin | -11.40% | -27.85% | -244.86% | -3816.33% | -59062.50% | - | Upgrade
|
| Profit Margin | -17.80% | -34.41% | -147.09% | -5126.02% | -124412.50% | - | Upgrade
|
| Free Cash Flow Margin | -8.67% | -28.92% | -238.10% | -3403.06% | -46087.50% | - | Upgrade
|
| EBITDA | -2.74 | -3.77 | -6.23 | -7.44 | -4.69 | -2.98 | Upgrade
|
| EBITDA Margin | -11.25% | -27.60% | -243.49% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.04 | 0.03 | 0.04 | 0.04 | 0.04 | 0.02 | Upgrade
|
| EBIT | -2.78 | -3.8 | -6.27 | -7.48 | -4.73 | -3 | Upgrade
|
| EBIT Margin | -11.40% | -27.85% | -244.86% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.